



VRL/SEC/EXCHANGE

06.08.2016

National Stock Exchange of India Ltd. 5 th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051	Dept. of Corporate Services The Stock Exchange, Mumbai 25 th Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai
---	---

Sub: Submission of Unaudited Financial results as on 30.06.2016

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results (provisional) along with limited review report for the quarter ended on 30.06.2016 which were taken on record by the Board of Directors at its meeting held on 06.08.2016.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED.


(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Website : www.venusremedies.com
www.vmrindia.com

email : info@venusremedies.com

CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

**UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30th June, 2016**

(Rs. in Millions)

S. No.	PARTICULARS	Quarter Ended on		Year ended on	
		30/06/2016 Unaudited	31/03/2016 Audited	30/06/2015 Unaudited	31/03/2016 Audited
1	Net Sales/ Income from operations				
	(a) Net Sales (Net of Excise Duty)	1015.15	1009.23	985.19	3969.84
	(b) Other Operating Income	16.30	(15.01)	3.93	57.11
	Total Income from Operation (Net)	1,031.45	994.22	989.12	4,026.95
2	Expenses				
	(a) Consumption of raw materials	662.17	571.31	590.01	2,419.98
	(b) (Increase)/ Decrease in stock in trade	(18.19)	(8.90)	5.55	(21.66)
	(c) Employee benefits expense	59.43	74.13	61.82	250.24
	(d) Depreciation & amortization expense	98.79	102.30	99.60	404.68
	(e) Other expenses	149.10	137.58	139.80	582.84
	Total expense	951.30	876.42	896.78	3,636.08
3	Profit from operations before other income , finance costs and exceptional items (1-2)	80.15	117.80	92.34	390.87
	EBIDTA (3+2(d))	178.94	220.10	191.94	795.55
4	Other income	1.24	3.66	1.04	6.65
5	Profit before finance costs and exceptional items (3+4)	81.39	121.46	93.38	397.52
6	Finance Costs	69.55	106.88	91.45	367.40
7	Profit after finance costs but before exceptional items (5-6)	11.84	14.58	01.93	30.12
8	Exceptional items	0.00	0.00	0.00	00.00
9	Profit from ordinary activities before tax (7+8)	11.84	14.58	01.93	30.12
10	Tax expense	0.00	18.08	0.00	18.08
11	Profit from ordinary activities after tax (9-10)	11.84	(3.50)	01.93	12.04
12	Exceptional items (net of tax expense	00.00	00.00	00.00	0.00
13	Net profit for the period (11-12)	11.84	(3.50)	01.93	12.04
14	Paid up Equity Share Capital	114.42	114.42	114.42	114.42
15	Reserves excluding revaluation reserves	N. A.	N. A.	N. A.	4,329.87
16	E.P.S - Basic not annualized for the qtr	1.03	(0.31)	0.17	1.05
	- Annualized	4.12	(1.24)	0.68	1.05

For **VENUS REMEDIES LIMITED**

CHAIRMAN & MANAGING DIRECTOR



Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on August 06, 2016.
2. The Company caters to only one segment i.e. "Pharmaceutical Formulations"
3. Previous quarter/period's figures have been regrouped/rearranged wherever necessary.

Date: 06.08.2016

For and on behalf of Board of Directors

For VENUS REMEDIES LIMITED
For VENUS REMEDIES LIMITED


CHAIRMAN & MANAGING DIRECTOR

Pawan Chaudhary
(Chairman & Managing Director)

DIN: 00435503



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1136-37, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Venus Remedies Limited
51-52, Industrial Area, Phase-I
Panchkula

We have reviewed the accompanying statement of un-audited Financial Results of **Venus Remedies Limited** for the Three months/Quarter ended 30.06.2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 06.08.2016
Place : Chandigarh

for J. K. Jain & Associates,
Chartered Accountants

J. K. Jain
(J.K. Jain)

Partner

M.No. 083140

FRN. 004025N

